DAB2IP, also known as AIP1 (ASK1 interacting protein), is a member of the Ras GTPase-activating protein family. It functions as a tumor suppressor and modulates various signal cascades related to cell proliferation, survival, apoptosis, and metastasis. It is involved in multiple key oncogenic pathways such as TNFα/NF-κB, WNT/β-catenin, PI3K/AKT, and androgen receptor signaling [1,4,5].

In cancer research, DAB2IP has been found to be significantly down-regulated in multiple types of cancer [1]. For instance, in breast cancer, DAB2IP inhibits glucose uptake under hypoxia by suppressing HIF-1α signals [2]. In colon cancer, it suppresses tumor malignancy by inhibiting GRP75-driven p53 ubiquitination [3]. In colorectal cancer, DAB2IP down-regulates HSP90AA1 to inhibit malignant biological behaviors [6]. In clear cell renal cell carcinoma, it stabilizes p27Kip1 via suppressing PI3K/AKT signaling [9]. Also, loss of DAB2IP in normal kidney epithelial cells impairs primary cilia formation, which is associated with renal tumorigenesis [8]. In KRAS-mutant colon cancer, its loss promotes tumor development by activating wild-type H-and N-RAS proteins and triggering inflammatory cascades [7].

In conclusion, DAB2IP serves as a crucial tumor suppressor, modulating various cellular functions and signaling pathways. Studies using gene-knockout or conditional-knockout mouse models (implied by in vivo experiments in references) have significantly contributed to understanding its role in cancer, highlighting its potential as a target for cancer therapies.